hackint0sh/New-Dataset huggingface dataset:
Study hypothesis and prospects: To make an initial estimate of the sensitivity and specificity of the NGPOD system for checking the positioning of the naso- or oro-gastric tube in the stomach, compared with the recognized gold standard, the chest X-ray. conditions: Intensive Care conditions: Nutrition studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 50 type: ESTIMATED name: pH indication with NGPOD measure: Ability of the NGPOD device to detect correct positioning of the gastric tube. measure: Probe malpositioning measure: Time to validate correct positioning of gastric tube measure: Evaluation of the "simplicity" of the procedures for using and interpreting the NGPOD system measure: x-ray manipulators time measure: Adverse events occurring during the study period measure: Ability of the NGPOD device to detect correct gastric tube positioning in a subgroup of patients sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hôpital Marie Lannelongue city: Le Plessis-Robinson zip: 92350 country: France name: Audrey IMBERT role: PRINCIPAL_INVESTIGATOR lat: 48.78889 lon: 2.27078 hasResults: False
nctId: NCT06316973 id: CS-1103-01 id: U01DA053054 type: NIH link: https://reporter.nih.gov/quickSearch/U01DA053054 briefTitle: A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants overallStatus: RECRUITING date: 2024-02-07 date: 2024-07 date: 2024-07 date: 2024-03-19 date: 2024-03-19 name: Clear Scientific, Inc. class: INDUSTRY name: National Institute on Drug Abuse (NIDA) briefSummary: The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants. conditions: Substance Use Disorders conditions: Methamphetamine Abuse conditions: Methamphetamine Intoxication studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, Double-Blind, Placebo-Controlled, Single Center Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CS-1103 Following Single, Ascending Intravenous Dose Administration in Healthy Participants primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: CS-1103 name: Sterile Saline measure: Number of participants with treatment-related adverse events (AEs) assessed by physical examinations measure: Number of participants with treatment-related adverse events (AEs) assessed by vital signs measure: Number of participants with treatment-related adverse events (AEs) assessed by electrocardiograms (ECGs) measure: Number of participants with treatment-related adverse events (AEs) assessed by laboratory parameters measure: Time course of CS-1103 blood and urine concentrations sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Dr. Vince Clinical Research status: RECRUITING city: Overland Park state: Kansas zip: 66212 country: United States name: Lori Adriano role: CONTACT phone: 913-333-3000 name: Steven Hull, M.D. role: PRINCIPAL_INVESTIGATOR lat: 38.98223 lon: -94.67079 hasResults: False
nctId: NCT06316947 id: FMCH-2024-32723 briefTitle: Developing and Pilot Testing an Intervention to Reduce Household Shisha Smoke Exposure Within Somali Homes overallStatus: NOT_YET_RECRUITING date: 2025-02-01 date: 2025-10-01 date: 2026-01-01 date: 2024-03-19 date: 2024-03-19 name: University of Minnesota class: OTHER briefSummary: Previous qualitative research among Somali American adults in Minnesota have identified high levels of hookah or shisha (hereafter shisha) use in Somali households. Household shisha use exposes all family members, including children, to secondhand smoke (SHS) that contains toxins that can cause many different acute and chronic disease, including increased levels of several cancers such as lung, bladder, and oral cancers. Despite the high levels of shisha use, gaps in the knowledge of the risks of shisha use and how to mitigate the potential harmful health consequences of shisha use exist among Somali Americans.
This study aims to pilot test the feasibility of a newly developed CHW-delivered intervention to reduce home shisha SHS exposure with n=15 Somali families. Pre-/post-measurements of family members' (1 adult and 1 child) urine or salivary cotinine levels will be obtained along with a brief pre-/post-survey to characterize household tobacco use and the presence of home smoke-free rules. conditions: Shisha studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: a feasibility pilot of the new CHW-delivered intervention to reduce home shisha SHS exposure with n=15 Somali families. primaryPurpose: OTHER masking: NONE count: 15 type: ESTIMATED name: CHW-delivered intervention measure: Recruitment rate measure: Retention rate measure measure: pre-/post- survey completion rates measure: pre-/post- biospecimen completion rates measure: shisha use changes measure: tobacco product use changes measure: smoke-free home rules measure: the cotinine levels of parents and children. sex: ALL minimumAge: 6 Months stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06316934 id: IRB202302181 briefTitle: Lavender Aromatherapy to Decrease Anxiety/Pain Perception During Office Hysteroscopy overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-07 date: 2024-08 date: 2024-03-19 date: 2024-04-05 name: University of Florida class: OTHER briefSummary: Office hysteroscopy is an invaluable practice to treat a myriad of gynecological processes. However, a limiting factor is the perceived pain and anxiety. In a randomized pilot study, treatment with lavender aromatherapy will significantly decrease the stress/anxiety levels associated with office hysteroscopy, as measured on a visual analogue scale and the Hospital Anxiety and Depression Scale (HADS) questionnaire when compared to control subjects receiving distilled water placebo. conditions: Anxiety conditions: Pain, Procedural studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The participants will be randomized into two arms - aromatherapy or placebo. The protocol will be the same for the two arms except that the towel held over the mouth will be scented either with lavender essential oil or distilled water. The clinic nurse will prepare the scented towel and hand it to the participant according to the random assignment. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: TRIPLE maskingDescription: Randomization will be performed once the patient agrees to participate and has signed the consent document. A random number generator will be used to designate each arm of the study. Odd numbers will be assigned to the aromatherapy arm while the even numbers will be assigned to the placebo arm. Each assignment will be placed into a sealed opaque numbered enveloped. After the participant has agreed to participate, the clinic nurse will open the envelope to identify the study arm. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 40 type: ESTIMATED name: Lavandula angustifolia, Aura Cacia name: Placebo measure: Determine the change in pain scores from baseline to immediate post-procedure. measure: Determine change in anxiety scores from baseline to immediate post-procedure. measure: Determine level of satisfaction after the procedure sex: FEMALE minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Florida city: Gainesville state: Florida zip: 32610 country: United States name: Tiffani-Amber Miller, MD role: CONTACT phone: 352-273-7660 email: tiffani12@ufl.edu name: Amira Quevedo, MD role: CONTACT phone: 352-273-7660 email: amiraquevedo@ufl.edu lat: 29.65163 lon: -82.32483 hasResults: False
nctId: NCT06316921 id: TCHIRB-11003008-E briefTitle: Epidural PCA on Pain Relief After L-spine Surgery overallStatus: COMPLETED date: 2021-06-01 date: 2021-12-31 date: 2021-12-31 date: 2024-03-19 date: 2024-03-19 name: Taipei City Hospital class: OTHER_GOV briefSummary: This study aimed to evaluate the effect of epidural patient-controlled analgesia (PCA) on postoperative pain relief after lumbar spine surgeries. The eligible patients received two types of postoperative pain management: PCA and standard pain treatment. Comparisons between the two groups were made in terms of postoperative pain level. conditions: Pain, Postoperative conditions: Lumbar Spine Degeneration conditions: Analgesia, Patient-Controlled conditions: Epidural Anesthesia studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 209 type: ACTUAL name: Epidural patient-controlled analgesia name: Standard postoperative pain management measure: Pain degree measure: The number of morphine injections measure: Length of hospitalization measure: Drainage amount sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taipei City Hospital city: Taipei country: Taiwan lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06316908 id: ERC-2019/A187 briefTitle: Permanent Celiac Plexus Block: Comparison of Pain Score in Unilateral and Bilateral Posterior Percutaneous Approach overallStatus: COMPLETED date: 2020-02-25 date: 2022-07-15 date: 2023-03-15 date: 2024-03-19 date: 2024-03-19 name: Sindh Institute of Urology and Transplantation class: OTHER briefSummary: The goal of this prospective, interventional, non-randomized study was to compare pain score in unilateral and bilateral posterior percutaneous neurolytic celiac plexus block (NCPB) in upper abdominal cancer patients.
Pain scores and adverse events at multiple time points post-procedure were recorded. conditions: Abdominal Cancer conditions: Cancer Pain conditions: Cancer of Pancreas studyType: INTERVENTIONAL phases: PHASE4 allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Unilateral Approach Group: Patients in this group have received a unilateral percutaneous posterior approach for NCPB. The procedure was performed under fluoroscopic guidance.
Bilateral Approach Group: Patients in this group have undergone a bilateral percutaneous posterior approach for NCPB, following the same procedural guidance. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 30 type: ACTUAL name: Unilateral Neurolytic Celiac Plexus Block with Absolute Alcohol name: Bilateral Neurolytic Celiac Plexus Block with Absolute Alcohol measure: Pain Score using the Visual Analog Scale measure: Change in Mean Arterial Pressure measure: Incidence of Patient-Reported Nausea Feeling measure: Incidence of Vomiting sex: ALL minimumAge: 20 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sindh Institute of Urology and Transplantation city: Karachi state: Sindh zip: 74200 country: Pakistan lat: 24.8608 lon: 67.0104 hasResults: False
nctId: NCT06316895 id: S2023-706 briefTitle: The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2027-04-01 date: 2029-12-31 date: 2024-03-19 date: 2024-03-20 name: Chinese PLA General Hospital class: OTHER briefSummary: 1. To evaluate the clinical outcomes of ultrasound-guided thermal ablation and thyroid surgery for the treatment of papillary thyroid carcinoma;
2. To develop and validate a artificial intelligence model to predict the outcomes of ultrasound-guided thermal ablation in the treatment of papillary thyroid carcinoma; conditions: Papillary Thyroid Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 3772 type: ESTIMATED name: thyroid surgery name: ultrasound-guided thermal ablation measure: rate of disease progression measure: Rate of complications measure: Rate of tumor disappearance sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06316882 id: ROCGAS 01 id: ROGCAS Study type: OTHER domain: ULSNA briefTitle: Opportunistic Gastric Cancer Screening acronym: ROCGAS overallStatus: RECRUITING date: 2023-02-03 date: 2024-07-31 date: 2024-12-31 date: 2024-03-19 date: 2024-03-19 name: Unidade Local De Saúde Do Norte Alentejano class: OTHER name: NOVA Medical School briefSummary: Endoscopic screening of gastric cancer combined with screening colonoscopy conditions: Gastric Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 139 type: ESTIMATED name: Screening endoscopy measure: number of gastric adenocarcinoma measure: number of pre-malignant lesions measure: Costs of screening endoscopy measure: Socio-demographic characteristics of population in screening program sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ULSNA status: RECRUITING city: Portalegre zip: 7300-853 country: Portugal name: Beatriz Mourato, MD role: CONTACT phone: 00351910311213 email: 2091@ulsna.min-saude.pt name: Beatriz Mourato, MD role: PRINCIPAL_INVESTIGATOR name: Guilherme Santos, MD role: PRINCIPAL_INVESTIGATOR name: Sara Morais, MD role: SUB_INVESTIGATOR name: Nuno Pratas, MD role: PRINCIPAL_INVESTIGATOR name: Filipa Taré, MD role: PRINCIPAL_INVESTIGATOR lat: 39.29379 lon: -7.43122 hasResults: False
nctId: NCT06316869 id: STVi briefTitle: Noninvasive Prediction of Portal Hypertension in Cirrhosis Using Sound Touch Viscoelastography overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2025-03-31 date: 2025-03-31 date: 2024-03-19 date: 2024-03-19 name: First Affiliated Hospital of Wenzhou Medical University class: OTHER briefSummary: The objective of this observational study is to investigate and validate the utility of the Sound Touch Viscoelastography(STVi) technique in patients with liver cirrhosis for noninvasive prediction of Portal hypertension (PH). The primary research questions it seeks to address are as follows:
The HVPG is considered as the gold standard in our study and STVi was employed to quantify the STVi index of the liver in patients with liver cirrhosis. Researchers will compare the two patients groups, HVPG≥10 mmHg and HVPG\<10 mmHg, to see the usage of STVi in the noninvasive prediction of PH. conditions: Portal Hypertension conditions: Cirrhosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 216 type: ESTIMATED measure: STVi index sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: the First Affiliated Hospital the First Affiliated Hospital city: Wenzhou state: Zhejiang zip: 325006 country: China lat: 27.99942 lon: 120.66682 hasResults: False
nctId: NCT06316856 id: BJGBYY-IIT-LCYJ-2024-002 briefTitle: CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2025-12-31 date: 2026-06-30 date: 2024-03-19 date: 2024-04-09 name: Beijing GoBroad Hospital class: OTHER briefSummary: This is a single-center, open-label, non-randomized, phase 1/2 study of anti-CD5 CAR-T cell therapy in patients with CD5+ relapsed or refractory T-cell malignancies. A bayesian optimal interval (BOIN) 12 design will be used to explore the optimal biological dose (OBD) from starting dose level 1: 1×10\^6 (±20%) to dose level 2: 2×10\^6 (±20%) in three cohorts (autologous, previous-transplant-donor or newly matched donor-derived CD5 CAR T cells). If the manufactured cells are not sufficient to meet the preassigned standard dose criteria, patients will be given infusion at a low dose level of 5×10\^5 (±20%) /kg. The primary objective is to evaluate the safety and tolerability of CD5 CAR T cell therapy in subjects, determine the OBD and recommend phase 2 dose (RP2D) in phase 1, and evaluate the efficacy of CD5 CAR T cell therapy in phase 2. The primary endpoint is the type and incidence of dose-limiting toxicity (DLT) within 28 days, and the incidence and severity of adverse events (AEs) within 30 days after CD5 CAR T-cell infusion in phase 1, the best overall response (BOR) at 3 months (± 1 week) after CD5 CAR T-cell infusion in phase 2. A total number of 54 subjects will be enrolled. conditions: T-Cell Acute Lymphocytic Leukemia conditions: Acute Lymphoblastic Leukemia, in Relapse conditions: Refractory Acute Lymphoblastic Leukemia studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 54 type: ESTIMATED name: Autologous CD5 CAR T-cells name: Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells name: Newly matched donor-derived CD5 CAR T-cells measure: Phase 1-The incidence and type of dose-limiting toxicity (DLT) measure: Phase 1-The incidence and severity of adverse events (AEs) measure: Phase 2-Antitumor effect measure: Phase 1-Objective response rate (ORR) measure: Phase 1-Pharmacokinetics of CD5 CAR T cells measure: Phase 1-The incidence and severity of adverse events (AEs). measure: Phase 1-Best overall response (BOR) rate. measure: Phase 2-Objective response rate (ORR) measure: Phase 2- The incidence and severity of AEs measure: Phase 2- Progression free survival (PFS) measure: Phase 2- Overall survival (OS). sex: ALL minimumAge: 1 Year maximumAge: 70 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06316843 id: BHC202 v2.1 briefTitle: Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2 acronym: PASC overallStatus: RECRUITING date: 2023-10-15 date: 2024-08 date: 2024-10 date: 2024-03-19 date: 2024-03-20 name: Bateman Horne Center class: OTHER briefSummary: To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the treatment of patients with prolonged symptoms caused by COVID-19. conditions: Long COVID conditions: PASC Post Acute Sequelae of COVID 19 studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Valacyclovir celecoxib dose 1 name: Valacyclovir celecoxib dose 2 name: Placebo measure: Fatigue assessed with the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue 7a Instrument sex: FEMALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bateman Horne Center status: RECRUITING city: Salt Lake City state: Utah zip: 84102 country: United States name: Lucinda Bateman, MD role: CONTACT phone: 801-359-7400 email: lbateman@batemanhornecenter.org name: Suzanne D Vernon, PhD role: CONTACT phone: (801) 359-7400 email: sdvernon@batemanhornecenter.org lat: 40.76078 lon: -111.89105 hasResults: False
nctId: NCT06316830 id: STUDY00000075 briefTitle: Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose acronym: Optimal Bup overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-06-30 date: 2027-04-30 date: 2024-03-18 date: 2024-03-18 name: Rhode Island Hospital class: OTHER name: Brown University briefSummary: The investigators aim to test the effectiveness of a high maintenance daily dose of buprenorphine (24 mg) for improving outcomes among patients who used fentanyl compared to the standard daily dose (16 mg).
The main question it aims to answer is: will patients who are randomly assigned to the high 24 mg maintenance dose, as compared to patients randomly assigned to the standard 16 mg maintenance dose, have improved retention in buprenorphine treatment (primary outcome), decreased use of non-prescribed opioids (secondary outcome), decreased opioid cravings (secondary outcome), and decreased risk of fatal and non-fatal opioid overdose (secondary outcome). conditions: Opioid Use Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 250 type: ESTIMATED name: Buprenorphine measure: Treatment Engagement measure: Use of non-prescribed opioids measure: Control of Opioid Cravings measure: Rate of Non-fatal or Fatal Opioid Overdose measure: Use of non-prescribed opioids sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06316817 id: 23-0184-E briefTitle: FloPatch for Prevention of Hypotension After Induction of General Anesthesia acronym: HI-CAP overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-03-01 date: 2026-03-02 date: 2024-03-18 date: 2024-03-18 name: Mount Sinai Hospital, Canada class: OTHER briefSummary: This study is being conducted to find out if a special device called FloPatch™, which sticks to a persons skin and uses ultrasound to check the blood flow in their neck, can tell if someone going to have low blood pressure after they get put to sleep for surgery. The investigators will be testing this in adults who are having elective non-heart surgery. Basically, the goal is to see if this device can help predict who might have low blood pressure during surgery.
Hypotension is a common side-effect of general anesthesia induction, and is related to adverse outcomes, including significantly increasing risk of one-year mortality. Even short durations of intraoperative hypotension have been associated with acute kidney injury (AKI) and myocardial injury. Myocardial injury after non-cardiac surgery (MINS) is a common postoperative complication associated with adverse cardiovascular outcomes, and intraoperative hypotension is believed to be involved in its development.
In the preoperative setting, a systematic review of 50 studies (2,260 patients) evaluating techniques to assess adult patients with refractory hypotension or signs of organ hypoperfusion found that half of all patients were fluid-responsive, pointing to volume status as a significant risk factor, while also presenting a challenge in distinguishing fluid-responders from non-responders. For surgical patients, preoperative fasting, hypertonic bowel preparations, anesthetic agents, and positive pressure ventilation all contribute to reduced effective circulating blood volume. Optimized fluid therapy remains the cornerstone of treatment of hypovolemia, with excellent effectiveness. Since the liberal use of fluids may result in fluid overload, which is associated with the development of pulmonary edema, wound infection, postoperative ileus, and anastomotic leakage, it is imperative to identify those patients who may benefit from it.
The hypothesis is that the corrected Flow Time (cFT) measured by the FloPatch will help predict hypotension after the induction of general anesthesia. conditions: Hypotension on Induction studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 172 type: ESTIMATED name: FloPatch measure: Prognostic ability of preoperative common carotid artery corrected Flow Time (cFT) measurement to predict Post Induction Hypotension(PIH). measure: Passive leg raising (PLR) in predicting Post Induction Hypotension(PIH). measure: Thresholds of common carotid artery corrected Flow Time (cFT) change during Passive Leg Raising (PLR) in predicting Post Induction Hypotension (PIH). measure: Thresholds of common carotid artery corrected Flow Time (cFT) change after Passive Leg Raising(PLR) in predicting Post Induction Hypotension (PIH). measure: Time required to get common carotid artery corrected Flow Time(cFT) data. measure: Common carotid artery corrected Flow Time (cFT) during induction correlation with Post Induction Hypotension(PIH). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mount Sinai Hospital city: Toronto state: Ontario zip: M5G 1X5 country: Canada lat: 43.70011 lon: -79.4163 hasResults: False